Swiss stocks - Factors to watch on Sept 14
14/09/2018 06:21
ZURICH/BERLIN, Sept 14 (Reuters) - Here are some of the main
factors that may affect Swiss stocks on Friday:
ROCHE ROG.S
The world's biggest producer of cancer drugs is stepping up
cost cuts in an efficiency drive made unavoidable by competition
from cut-price copies of three mega-brands from its famed U.S.
Genentech biotech stable. urn:newsml:reuters.com:*:nL5N1VZ6CS
Chief Executive Severin Schwan told Reuters he was confident
he could fill the sales gap but expects only "moderate growth"
into 2019 - helped by newer drugs such as Ocrevus for multiple
sclerosis (MS) - before a "re-acceleration" around 2021-22.
COMPANY STATEMENTS E-CH
* Basler Kantonalbank BSKP.S : Simone Westerfeld named
interim CEO of BKB; former CEO Lachapelle nominated as chairman
of Raiffeisen RFSHW.UL urn:newsml:reuters.com:*:nFWN1W0030
* Basler Kantonalbank: interim provisional result on the
takeover bid for Bank Cler AG BC.S ; minimum tendering rate of
90 percent of the offer prospectus has been fulfilled
urn:newsml:reuters.com:*:nFWN1W0032
* Aryzta AG ARYN.S : has received unanimous consent of its
lenders to amend its existing facilities agreement urn:newsml:reuters.com:*:nFWN1W0036
* Landis & Gyr LANDI.S said it has taken over management
of 660,000 payment points for Caruna Oy in Finland. LANDI.S
* Roche said it won FDA approval of Actemra given as a shot
for active systemic juvenile idiopathic arthritis. ROG.S
* Jungfraubahn Holding AG JFN.S was reprimanded by Swiss
financial watchdog FINMA for violating market conduct rules by
improperly influencing the year-end price of its own shares on
between 2014 and 2016. The cable-car company said it cooperated
with the probe and has taken steps to address the situation.
JFN.S
* Arundel ARONL.S said the pension fund of a company
listed in the United States had bought more of its treasury
shares, taking its total ownership to around 7.2 percent of the
company. ARONL.S
* Coltene CLTN.S announced the terms of its rights
offering in connection with the partial financing of its planned
acquisition of Scican and Micro.
* Aevis Victoria SA AEVS.S : H1 total revenues decreased by
5.2% to CHF 319.1 million; H1 net loss 1.6 million, versus net
profit of CHF 12.2 million in H1 2017 urn:newsml:reuters.com:*:nFWN1W0038
ECONOMY M-CH
No Swiss economic data scheduled.
(Reporting by Zurich newsroom and Berlin Speed Desk)
((+41 58 306 7336; zurich.newsroom@thomsonreuters.com))
((For Top News in a multimedia Web format on Eikon visit:
https://bit.ly/2NDFd6g
FOR RELATED PRICES, NEWS AND OTHER TOPICS, DOUBLE-CLICK ON:
Daily Swiss stock market report in German................ .SDE
All SMI constituent stocks............................ 0#.SSMI
News on major Swiss stock price moves.................. CH-HOT
FTSE Eurotop 300 index................................ .FTEU3
DJ STOXX index........................................ .STOXX
Top 10 STOXX sectors............................. .PGL.STOXXS
Top 10 EUROSTOXX sectors........................ .PGL.STOXXES
Top 10 Eurotop 300 sectors....................... .PGL.FTEU3S
Top 25 European pct gainers... .PG.PEUR , losers... .PL.PEUR
Swiss mid-cap index .SSMI SMI futures 0#SMI:
Swiss all-share index .SSHI Market statistics CH/STATS1
Swiss market digest .AD.S Sector overview CH/SECTOR1
All Swiss news CH Swiss research news CH-RCH
All equity news E
INTERNET ADDRESSES:
Swiss Exchange www.swx.ch/
STOXX Ltd www.stoxx.com
SPEED GUIDES: EQUITY EQUITY/NEWS1 EUR/EQUITY
SWITZERLAND REUTERS ))